[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631366":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":42,"collaborators":44,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":74,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Institute of Tropical Medicine, Belgium","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"MVA-BN or LC16m8 vaccinated","Participants vaccinated with MVA-BN or LC16m8 vaccine during the national vaccination campaign",[12],"Procedure: blood sample collection",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","blood sample collection","10 mL of blood will be collected at every visit and additional 20 mL blood samples will be taken from a subgroup of participants at every visit.",[9],null,[21,32,37],{"facility":22,"status":19,"city":23,"state":19,"zip":19,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":19},"Centre Convivial Kasa-Vubu","Kinshasa","Democratic Republic of the Congo","CD",{"type":27,"coordinates":28},"Point",[29,30],15.31357,-4.32758,{"lat":30,"lon":29},{"facility":33,"status":19,"city":23,"state":19,"zip":19,"country":24,"countryCode":25,"cosmosGeoPoint":34,"geoPoint":36,"contacts":19},"Kinoise",{"type":27,"coordinates":35},[29,30],{"lat":30,"lon":29},{"facility":38,"status":19,"city":23,"state":19,"zip":19,"country":24,"countryCode":25,"cosmosGeoPoint":39,"geoPoint":41,"contacts":19},"Kokolo",{"type":27,"coordinates":40},[29,30],{"lat":30,"lon":29},{"type":43,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[45,48,50],{"name":46,"class":47},"Institut National de Recherche Biomédicale (INRB). Kinshasa, Democratic Republic of Congo","UNKNOWN",{"name":49,"class":47},"Programme Elargi de Vaccination de République Démocratique du Congo",{"name":51,"class":47},"National Institute of Public Health of the Democratic Republic of the Congo","100631366","phase-4-mpox-biology-outcome-transmission-and-epidemiology---tracking-the-immune-response-after-mpox-vaccination-mbote-traxx-clinical-study-to-monitor-the-immunological-response-following-mpox-vaccination-in-the-city-of-kinshasa-democratic-republic-of-the-congo-100631366",false,"NCT07499739","Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo","Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination","MBOTE-TRAXX","Inclusion Criteria:\n\n* Any person aged 18 years old or over at the time of giving informed consent, of any gender\n* Participant received the MVA-BN or LC16m8 mpox vaccine as part of the national vaccination campaign\n* Participant has the capacity and willingness to give informed written consent\n* Participant agrees to adhere to the study's follow-up schedule",true,"ALL","18 Years",{"count":64,"type":65},300,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of a routine mpox vaccination campaign in Kinshasa, Democratic Republic of the Congo (DRC). Participants will be followed up at multiple time points after vaccination in order to assess the kinetics and durability of the immune response by collection of blood samples. It is planned to include approximately 150 participants vaccinated with MVA-BN and 150 participants vaccinated with LC16m8.",[71],"Mpox",[73],"mpox vaccines","ACTIVE_NOT_RECRUITING","2026-06-09",{"date":77,"type":78},"2026-06-11","ACTUAL",{"date":80,"type":78},"2026-05-15",{"date":82,"type":65},"2028-12-15",{"name":5,"class":6},3]